|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GAS2L1 |
Gene summary for GAS2L1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GAS2L1 | Gene ID | 10634 |
| Gene name | growth arrest specific 2 like 1 | |
| Gene Alias | GAR22 | |
| Cytomap | 22q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q99501 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10634 | GAS2L1 | P1T-E | Human | Esophagus | ESCC | 2.74e-10 | 5.01e-01 | 0.0875 |
| 10634 | GAS2L1 | P2T-E | Human | Esophagus | ESCC | 2.08e-12 | 1.05e-01 | 0.1177 |
| 10634 | GAS2L1 | P4T-E | Human | Esophagus | ESCC | 1.17e-14 | 4.25e-01 | 0.1323 |
| 10634 | GAS2L1 | P5T-E | Human | Esophagus | ESCC | 1.07e-14 | 1.51e-01 | 0.1327 |
| 10634 | GAS2L1 | P8T-E | Human | Esophagus | ESCC | 3.15e-08 | 1.31e-01 | 0.0889 |
| 10634 | GAS2L1 | P9T-E | Human | Esophagus | ESCC | 8.90e-15 | 4.17e-01 | 0.1131 |
| 10634 | GAS2L1 | P10T-E | Human | Esophagus | ESCC | 2.32e-21 | 2.70e-01 | 0.116 |
| 10634 | GAS2L1 | P11T-E | Human | Esophagus | ESCC | 5.92e-11 | 4.01e-01 | 0.1426 |
| 10634 | GAS2L1 | P12T-E | Human | Esophagus | ESCC | 1.36e-21 | 3.23e-01 | 0.1122 |
| 10634 | GAS2L1 | P15T-E | Human | Esophagus | ESCC | 7.72e-22 | 4.55e-01 | 0.1149 |
| 10634 | GAS2L1 | P16T-E | Human | Esophagus | ESCC | 1.23e-11 | 1.35e-01 | 0.1153 |
| 10634 | GAS2L1 | P17T-E | Human | Esophagus | ESCC | 9.37e-06 | 3.33e-01 | 0.1278 |
| 10634 | GAS2L1 | P19T-E | Human | Esophagus | ESCC | 6.35e-09 | 6.81e-01 | 0.1662 |
| 10634 | GAS2L1 | P20T-E | Human | Esophagus | ESCC | 3.67e-14 | 3.72e-01 | 0.1124 |
| 10634 | GAS2L1 | P21T-E | Human | Esophagus | ESCC | 1.38e-34 | 6.55e-01 | 0.1617 |
| 10634 | GAS2L1 | P22T-E | Human | Esophagus | ESCC | 5.79e-24 | 3.74e-01 | 0.1236 |
| 10634 | GAS2L1 | P23T-E | Human | Esophagus | ESCC | 3.29e-26 | 5.15e-01 | 0.108 |
| 10634 | GAS2L1 | P24T-E | Human | Esophagus | ESCC | 5.40e-17 | 3.63e-01 | 0.1287 |
| 10634 | GAS2L1 | P26T-E | Human | Esophagus | ESCC | 1.66e-30 | 4.35e-01 | 0.1276 |
| 10634 | GAS2L1 | P27T-E | Human | Esophagus | ESCC | 3.08e-24 | 3.37e-01 | 0.1055 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
| GO:0031668111 | Esophagus | ESCC | cellular response to extracellular stimulus | 168/8552 | 246/18723 | 4.93e-13 | 2.23e-11 | 168 |
| GO:0031669110 | Esophagus | ESCC | cellular response to nutrient levels | 148/8552 | 215/18723 | 4.58e-12 | 1.76e-10 | 148 |
| GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
| GO:0009267110 | Esophagus | ESCC | cellular response to starvation | 110/8552 | 156/18723 | 2.63e-10 | 7.37e-09 | 110 |
| GO:004259419 | Esophagus | ESCC | response to starvation | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
| GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
| GO:00705078 | Esophagus | ESCC | regulation of microtubule cytoskeleton organization | 99/8552 | 148/18723 | 1.43e-07 | 2.29e-06 | 99 |
| GO:00726985 | Esophagus | ESCC | protein localization to microtubule cytoskeleton | 43/8552 | 54/18723 | 3.28e-07 | 4.61e-06 | 43 |
| GO:00443804 | Esophagus | ESCC | protein localization to cytoskeleton | 45/8552 | 58/18723 | 6.89e-07 | 8.99e-06 | 45 |
| GO:00311094 | Esophagus | ESCC | microtubule polymerization or depolymerization | 77/8552 | 122/18723 | 7.60e-05 | 5.68e-04 | 77 |
| GO:00311104 | Esophagus | ESCC | regulation of microtubule polymerization or depolymerization | 57/8552 | 88/18723 | 2.32e-04 | 1.44e-03 | 57 |
| GO:00328864 | Esophagus | ESCC | regulation of microtubule-based process | 134/8552 | 240/18723 | 9.44e-04 | 4.80e-03 | 134 |
| GO:0035372 | Esophagus | ESCC | protein localization to microtubule | 15/8552 | 18/18723 | 1.20e-03 | 5.88e-03 | 15 |
| GO:007149620 | Oral cavity | OSCC | cellular response to external stimulus | 186/7305 | 320/18723 | 2.56e-12 | 1.05e-10 | 186 |
| GO:003166819 | Oral cavity | OSCC | cellular response to extracellular stimulus | 141/7305 | 246/18723 | 3.99e-09 | 8.95e-08 | 141 |
| GO:003166720 | Oral cavity | OSCC | response to nutrient levels | 245/7305 | 474/18723 | 1.02e-08 | 2.10e-07 | 245 |
| GO:000701520 | Oral cavity | OSCC | actin filament organization | 230/7305 | 442/18723 | 1.37e-08 | 2.77e-07 | 230 |
| GO:003166918 | Oral cavity | OSCC | cellular response to nutrient levels | 121/7305 | 215/18723 | 1.96e-07 | 3.17e-06 | 121 |
| GO:004259416 | Oral cavity | OSCC | response to starvation | 111/7305 | 197/18723 | 5.68e-07 | 8.19e-06 | 111 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GAS2L1 | SNV | Missense_Mutation | rs772163549 | c.322N>A | p.Gly108Ser | p.G108S | protein_coding | tolerated(0.4) | benign(0.258) | TCGA-5T-A9QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD | |
| GAS2L1 | SNV | Missense_Mutation | rs746848845 | c.221N>A | p.Arg74His | p.R74H | protein_coding | tolerated(0.21) | benign(0.369) | TCGA-EW-A3U0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
| GAS2L1 | SNV | Missense_Mutation | novel | c.935N>G | p.Glu312Gly | p.E312G | protein_coding | tolerated(0.08) | possibly_damaging(0.715) | TCGA-XX-A899-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR | |
| GAS2L1 | insertion | Frame_Shift_Ins | novel | c.707_708insCCCACCTGCTTATTTCC | p.Val237ProfsTer19 | p.V237Pfs*19 | protein_coding | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| GAS2L1 | deletion | Frame_Shift_Del | novel | c.678delC | p.Met227Ter | p.M227* | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| GAS2L1 | deletion | Frame_Shift_Del | novel | c.878delC | p.Pro293HisfsTer28 | p.P293Hfs*28 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
| GAS2L1 | SNV | Missense_Mutation | novel | c.1964N>A | p.Arg655His | p.R655H | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.683) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| GAS2L1 | SNV | Missense_Mutation | rs376278123 | c.1451N>A | p.Arg484Gln | p.R484Q | protein_coding | tolerated(0.25) | benign(0) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| GAS2L1 | SNV | Missense_Mutation | novel | c.697G>T | p.Gly233Trp | p.G233W | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| GAS2L1 | SNV | Missense_Mutation | c.164N>A | p.Gly55Glu | p.G55E | protein_coding | tolerated(0.29) | possibly_damaging(0.841) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |